TALEN

TALEN1-fscn1a

ID
ZDB-TALEN-150526-1
Name
TALEN1-fscn1a
Previous Names
None
Target
Target Sequence 1
5' - CGGCTTCAAGATCAATGCAT - 3'
Target Sequence 2
5' - CCAAATCTGCTTCTTCT - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
None
Genome Resources
None
Target Location
Constructs
No data available
Genomic Features
Genomic Feature Affected Genomic Regions
zd1011 fscn1a
zd1012 fscn1a
zd1013 fscn1a
Expression
Gene expression in Wild Types + TALEN1-fscn1a
No data available
Phenotype
Phenotype resulting from TALEN1-fscn1a
No data available
Phenotype of all Fish created by or utilizing TALEN1-fscn1a
Phenotype Fish Conditions Figures
sympathetic nervous system decreased size, abnormal fscn1azd1011/zd1011 standard conditions Fig. 7 with image from Boer et al., 2015
pharyngeal arch 1 morphology, abnormal fscn1azd1011/zd1011 chemical treatment: pharmaceutical Fig. 6 with image from Boer et al., 2015
palatoquadrate cartilage absent, abnormal fscn1azd1011/zd1011 control Fig. 5 with imageFig. 6 with image from Boer et al., 2015
pharyngeal arch 1 cranial neural crest misrouted, abnormal fscn1azd1011/zd1011 standard conditions Fig. 4 with image from Boer et al., 2015
pharyngeal arch 1 neural crest cell migration process quality, abnormal fscn1azd1011/zd1011 standard conditions Fig. 4 with image from Boer et al., 2015
splanchnocranium morphology, abnormal fscn1azd1011/zd1011 chemical treatment: pharmaceutical Fig. 6 with image from Boer et al., 2015
splanchnocranium morphology, abnormal fscn1azd1011/zd1011 standard conditions Fig. 2 with imageFig. 6 with imageFig. 8 with image from Boer et al., 2015
cranial neural crest misrouted, abnormal fscn1azd1011/zd1011 standard conditions Fig. 4 with image from Boer et al., 2015
pharyngeal arch 1 absent, abnormal fscn1azd1011/zd1011 standard conditions Fig. 5 with image from Boer et al., 2015
Meckel's cartilage absent, abnormal fscn1azd1011/zd1011 control Fig. 5 with imageFig. 6 with image from Boer et al., 2015
swim bladder morphology, abnormal fscn1azd1011/zd1011 standard conditions Fig. 2 with image from Boer et al., 2015
cranial neural crest neural crest cell migration process quality, abnormal fscn1azd1011/zd1011 standard conditions Fig. 4 with image from Boer et al., 2015
Meckel's cartilage absent, abnormal fscn1azd1011/zd1011 chemical treatment: pharmaceutical Fig. 6 with image from Boer et al., 2015
sympathetic nervous system malformed, abnormal fscn1azd1011/zd1011 standard conditions Fig. 7 with image from Boer et al., 2015
heart morphology, abnormal fscn1azd1011/zd1011 standard conditions Fig. 2 with image from Boer et al., 2015
sympathetic nervous system development process quality, abnormal fscn1azd1011/zd1011 standard conditions Fig. 7 with imageFig. S9 with image from Boer et al., 2015
palatoquadrate cartilage absent, abnormal fscn1azd1011/zd1011 chemical treatment: pharmaceutical Fig. 6 with image from Boer et al., 2015
pharyngeal arch 1 morphology, abnormal fscn1azd1011/zd1011 control Fig. 5 with imageFig. 6 with image from Boer et al., 2015
enteric neuron decreased amount, abnormal fscn1azd1011/zd1011; w37Tg standard conditions Fig. 7 with image from Boer et al., 2015
sympathetic nervous system malformed, abnormal fscn1azd1011/zd1011; zdf15Tg standard conditions Fig. 7 with image from Boer et al., 2015
sympathetic nervous system development process quality, abnormal fscn1azd1011/zd1011; zdf15Tg standard conditions Fig. 7 with image from Boer et al., 2015
cranial neural crest filopodium decreased amount, abnormal fscn1azd1012/zd1012; vu234Tg control Fig. 3 with imageFig. 6 with imageFig. 8 with image from Boer et al., 2015
cranial neural crest filopodium decreased length, abnormal fscn1azd1012/zd1012; vu234Tg chemical treatment: pharmaceutical Fig. 6 with image from Boer et al., 2015
cranial neural crest filopodium decreased amount, abnormal fscn1azd1012/zd1012; vu234Tg chemical treatment: pharmaceutical Fig. 6 with image from Boer et al., 2015
cranial neural crest filopodium decreased length, abnormal fscn1azd1012/zd1012; vu234Tg control Fig. 3 with imageFig. 6 with imageFig. 8 with image from Boer et al., 2015
splanchnocranium morphology, abnormal fscn1azd1011/zd1011 + MO2-cxcr4a standard conditions Fig. 8 with image from Boer et al., 2015
sympathetic nervous system development process quality, abnormal fscn1azd1011/zd1011 + MO2-cxcr4a standard conditions Fig. S9 with image from Boer et al., 2015
cranial neural crest filopodium decreased amount, abnormal fscn1azd1012/zd1012; vu234Tg + MO2-cxcr4a standard conditions Fig. 8 with image from Boer et al., 2015
cranial neural crest filopodium decreased length, abnormal fscn1azd1012/zd1012; vu234Tg + MO2-cxcr4a standard conditions Fig. 8 with image from Boer et al., 2015
Citations